BTIG Thinks SeaSpine Holdings’ Stock is Going to Recover

By Carrie Williams

In a report issued on August 1, Ryan Zimmerman from BTIG maintained a Buy rating on SeaSpine Holdings (SPNEResearch Report), with a price target of $20. The company’s shares closed on Friday at $12.92, close to its 52-week low of $12.15.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 23.8% and a 66.7% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.

SeaSpine Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $20.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.75 and a one-year low of $12.15. Currently, SeaSpine Holdings has an average volume of 49.33K.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, Richard Caruso, a Major Shareholder at SPNE sold 5,020 shares for a total of $76,153.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SeaSpine Holdings Corp. is a medical technology company, which focuses on design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.